Literature DB >> 6694521

Interaction of (+)- and (-)-3-PPP with the dopamine receptor in the anterior pituitary gland.

M Mikuni, G A Gudelsky, M Simonovic, H Y Meltzer.   

Abstract

The interaction of the enantiomers of the novel dopamine agonist, 3-PPP (3-hydroxyphenyl)-N-n-piperidine) with the dopamine receptor in the anterior pituitary gland was examined. Both (+)- and (-)-3-PPP were effective in suppressing the elevation in serum prolactin (PRL) concentrations in rats treated with alpha-methyl-paratyrosine, an inhibitor of dopamine synthesis. The (+)-enantiomer was slightly more potent than the (-)-enantiomer in this regard. In addition, the secretion of PRL from anterior pituitary tissue under in vitro conditions was significantly inhibited by both isomers of 3-PPP, with (+)-3-PPP being approximately 10 times more potent than (-)-3-PPP. Both (+)- and (-)-3-PPP displaced 3H-(-)-N-n-propylnorapomorphine (3H-NPA) and 3H-spiperone from bovine anterior pituitary membranes. The Hill coefficients of (+)- and (-)-3-PPP for the displacement of 3H-spiperone were 0.6 and 0.7, respectively. These results are consistent with the view that the (+)- and (-)-enantiomer exhibit dopamine agonist effects at dopamine receptor sites in the anterior pituitary gland. However, (+)-3-PPP demonstrated marked differences in affinity for 3H-NPA- and 3H-spiperone labeled-sites, whereas (-)-)3-PPP showed the same order of affinity for these two sites. In view of these results and the fact that (-)-3-PPP has also been characterized as a dopamine antagonist at postsynaptic receptor sites in the striatum, (-)-3-PPP might be best described as a partial agonist at pituitary dopamine receptors. Moreover, these data are suggestive of a similarity, at least on a pharmacological basis, between dopamine autoreceptors and dopamine receptors in the anterior pituitary gland.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6694521     DOI: 10.1016/0024-3205(84)90595-2

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  7 in total

1.  Dopamine D2 receptors in brain and anterior pituitary recognize agonist and antagonist actions of (-)-3-PPP.

Authors:  S R George; M Watanabe; P Seeman
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

2.  Neuroendocrine profile of SDZ HDC-912 and OPC-4392, two new atypical antipsychotic drugs, in schizophrenic patients.

Authors:  F Duval; M C Mokrani; J P Macher; M A Crocq; J O Castro; P Bailey; X Lataste
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 3.  Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence.

Authors:  D Clark; S Hjorth; A Carlsson
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

4.  Postsynaptic dopamine agonistic effects of 3-PPP enantiomers revealed by bilateral 6-hydroxy-dopamine lesions and by chronic reserpine treatment in rats.

Authors:  J Arnt; J Hyttel
Journal:  J Neural Transm       Date:  1984       Impact factor: 3.575

5.  Effects of (-)3-PPP on acquisition and retention of a conditioned avoidance response in the rat.

Authors:  S Ahlenius; T Archer; B Tandberg; V Hillegaart
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

6.  BMY-14802 reverses the reduction of striatal dopamine release induced by (+)-3-[3-hydroxyphenyl]-N-(1-propyl)piperidine.

Authors:  A Kanzaki; K Okumura; H Ujike; K Tsuchida; K Akiyama; S Otsuki
Journal:  J Neural Transm Gen Sect       Date:  1992

7.  Differential action of bromocriptine on nigrostriatal versus mesolimbic dopaminergic neurons.

Authors:  A C Barton; K E Moore; K T Demarest
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.